Physician profile
Thomas C Mitchell
NPI 1376751909
$6,597.68
in general payments reported to CMS, 2019-2025
29 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $3,158 · 2021: $263 · 2022: $342 · 2023: $486 · 2024: $623 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,190.96 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $311.63 | 2021-2024 | Minimed 780g |
| Amgen INC. | $291.56 | 2020-2025 | Tepezza, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $273.19 | 2019-2020 | |
| Insulet Corporation | $229.18 | 2021-2025 | Omnipod |
| Abbott Laboratories | $207.54 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $157.55 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $104.35 | 2023-2025 | Ozempic, Rybelsus |
| Cequr Corporation | $101.62 | 2022-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $78.19 | 2022-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.87 | 2019-2023 | Jardiance |
| Dexcom, INC. | $62.70 | 2020-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $61.13 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $60.21 | 2021-2024 | |
| Medtronic Minimed, INC. | $51.48 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $46.33 | 2023-2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals Lp | $40.01 | 2019-2022 | |
| Ibsa Pharma INC. | $36.55 | 2020-2025 | Tirosint, Licart, Flector |
| Nevro Corp. | $36.54 | 2023-2024 | Senza |
| Senseonics, Incorporated | $29.00 | 2019 | |
| Gilead Sciences, INC. | $27.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.57 | 2023 | |
| Astellas Pharma US INC | $20.19 | 2024 | Veozah |
| Antares Pharma, INC. | $16.74 | 2024 | Xyosted |
| Lifescan, INC. | $15.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.83 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.77 | 2019 | |
| Esperion Therapeutics, INC. | $14.52 | 2020 | |
| Abbvie INC. | $13.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.